Tumor-infiltrating macrophages induce apoptosis in activated CD8+ T cells by a mechanism requiring cell contact and mediated by both the cell-associated form of TNF and nitric oxide

Journal of Immunology

Volumn 167, Issue 10, 2001, Pages 5583-5593

  Saio, M ^a   Radoja, S ^a   Marino, M ^a   Frey, A B ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ANTIGEN; CD8 ANTIGEN; FAS LIGAND; GAMMA INTERFERON; NITRIC OXIDE; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CELL CONTACT; CELL KILLING; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; MACROPHAGE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL;

EID: 0035889886     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.167.10.5583     Document Type: Article

References (64)

1. Improved in vivo efficacy of tumor-infiltrating lymphocytes after restimulation with irradiated tumor cells in vitro
2. Therapy with cultured T cells: Principles revisited
3. Sensitizing T-lymphocytes for adoptive immunotheraphy by vaccination with wild-type or cytokine gene-transduced melanoma
4. Infiltration of tumors by systemically transferred tumor-reactive T lymphocytes is required for antitumor efficacy
5. Tumor regression after adoptive transfer of effector T cells is independent of perforin or Fas ligand (APO-IL/CD95L)
6. Adoptive T-cell immunotherapy of cancer
7. Role of host antigen receptor-bearing and antigen receptor-negative cells in immune response to rat adenocarcinoma 13762
8. + anti-tumor T cells requires tumor expression of cell surface MHC class II molecules
9. Gene therapy for metastatic brain tumors by vaccination with granulocyte-macrophage colony-stimulating factor-transduced tumor cells
10. Direct in vitro evidence and in vivo analysis of the antiangiogenesis effects of interleukin 12
11. Angiogenesis and cancer metastasis
12. Hypoxia-mediated apoptosis from angiogenesis inhibition underlies tumor control by recombinant interleukin 12
13. How tumors escape immune destruction and what we can do about it
14. Protective immunity is induced in murine colon carcinoma cells by the expression of interleukin-12 or interleukin-18, which activate type 1 helper T cells
15. Developing recombinant and synthetic vaccines for the treatment of melanoma
16. New opportunities for the development of cancer immunotherapies
17. Cancer vaccines
18. Escape from host-antitumor immunity
19. Cancer-induced defective cytotoxic T lymphocyte effector function: Another mechanism how antigenic tumors escape immune-mediated killing
20. T cell-tumor cell: A fatal interaction?
21. The Fas counterattack: Cancer as a site of immune privilege
22. Tumor expression of Fas ligand (CD95L) and the consequences
23. The role of Fas/FasL in immuno-suppression induced by human tumors
24. Human melanoma cells do not express Fas (APO-1/CD95) ligand
25. Alterations in T cells of cancer-bearers: Whence specificity?
26. Mice bearing late-stage tumors have normal functional systemic T cell responses in vitro and in vivo
27. Characterization of tumor necrosis factor-deficient mice
28. A fluorometric assay for the measurement of nitrite in biological samples
29. IFN-γ + LPS induction of iNOS is modulated by ERK, JNK/SAPK, and p38(mapk) in a mouse macrophage cell line
30. Identification of protein kinase C isoforms involved in interferon-γ-induced expression of inducible nitric oxide synthase in murine BV2 microglia
31. Interferon (IFN)-γ and herpes simplex virus/tumor necrosis factor-α synergistically induce nitric oxide synthase 2 in macrophages through cooperative action of nuclear factor-κB and IFN regulatory factor-1
32. Myosin V and iNOS expression is enhanced in J774 murine macrophages treated with IFN-γ
33. STAT1 is required for iNOS activation, but not IL-6 production in murine fibroblasts
34. Apoptosis and apoptosis-related proteins (Fas, Fas ligand, Blc-2, p53) in lymphoid elements of human ovarian tumors
35. Expressions of Fas ligand and other apoptosis-related genes and their prognostic significance in epithelial ovarian neoplasms
36. Tumour infiltrating lymphocytes in relation to tumour angiogenesis, apoptosis and prognosis in patients with large cell lung carcinoma
37. Expression of Fas (CD95/APO-1) ligand by human breast cancers: Significance for tumor immune privilege
38. Mechanisms of apoptosis in T cells from patients with renal cell carcinoma
39. Fas ligand is expressed on human squamous cell carcinomas of the head and neck, and it promotes apoptosis of T lymphocytes
40. Immune cells in the tumor microenvironment: Mechanisms responsible for functional and signaling defects
41. Interferon γ eliminates responding CD4 T cells during mycobacterial infection by inducing apoptosis of activated CD4 T cells
42. Immune suppression by recombinant interleukin (rIL)-12 involves interferon γ induction of nitric oxide synthase 2 (iNOS) activity: Inhibitors of NO generation reveal the extent of rIL-12 vaccine adjuvant effect
43. γ interferon modulates CD95 (Fas) and CD95 ligand (Fas-L) expression and nitric oxide-induced apoptosis during the acute phase of Trypanosoma cruzi infection: A posible role in immune response control
44. Functional switching of macrophage responses to tumor necrosis factor-α (TNF α) by interferons: Implications for the pleiotropic activities of TNF α
45. Differential regulation of gene expression during macrophage activation with a polyribonucleotide: The role of endogenously derived IFN
46. Expression of interferon-β during the triggering phase of macrophage cytocidal activation: Evidence for an autocrine/paracrine role in the regulation of this state
47. Induction of the synthesis of TNF receptors by interferon-γ
48. Differential effects of type I IFN and IFN-γ on the binding of TNF to receptors in two human cell lines
49. Ligand passing: The 75-kDa tumor necrosis factor (TNF) receptor recruits TNF for signaling by the 55-kDa TNF receptor
50. Tumor necrosis factor induces rapid production of 1′2′diacylglycerol by a phosphatidylcholine-specific phospholipase C
51. Induction of apoptosis in mature T cells by tumour necrosis factor
52. Comparison of tumor necrosis factor-α effect on the expression of iNOS in macrophage and cardiac myocytes
53. Activated macrophages direct apoptosis and suppress mitosis of mesangial cells
54. Nitric oxide causes apoptosis in pulmonary vascular smooth muscle cells
55. Cytokine-induced, nitric oxide-dependent, intracellular antirickettsial activity of mouse endothelial cells
56. Nitric oxide sensitizes ovarian tumor cells to Fas-induced apoptosis
57. Cytolytic mechanisms of activated macrophages: TNF and L-arginine-dependent mechanisms act synergistically as the major cytolytic mechanisms of activated macrophages
58. Nitric oxide-induced apoptotic cell death in the acute phase of Trypanosoma cruzi infection in mice
59. γ interferon stimulates fat alveolar macrophages to kill Pneumocystis carinii by L-arginine- and tumor necrosis factor-dependent mechanisms
60. TNF-α synergizes with IFN-γ in mediating killing of Leishmania mojor through the induction of nitric oxide
61. Nitric oxide is required for effective innate immunity against Klebsiella pneumoniae
62. Suppression of apoptosis by nitric oxide via inhibition of interleukin-1β-converting enzyme (ICE)-like and cysteine protease protein (CPP)-32-like proteases
63. Apoptosis of vascular smooth muscle cells induced by in vitro stimulation with interferon-γ, tumor necrosis factor-α, and interleukin-1β
64. Nitric oxide suppresses apoptosis via interrupting caspase activation and mitochondrial dysfunction in cultured hepatocytes